Precigen Inc (PGEN)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Precigen Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 18 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 6.30 $ — 100% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
NeutralPrecigen ist ein Gen-/Immuntherapie-Unternehmen; die geprüften SEC-Berichte belegen keinen wesentlichen KI-Bezug — künstliche Intelligenz taucht nur als allgemeine regulatorische Floskel auf, weder als Umsatzquelle noch als konkretes operatives Werkzeug oder Geschäftsrisiko.
View the full file — quotes, sources, reviewed filings
„The rapid evolution of AI will require the application of significant resources to design, develop, test and maintain such systems to help ensure that AI is implemented in accordance with applicable law and regulation and in a socially responsible manner and to minimize any real or perceived unintended harmful impacts."
Die rasche Entwicklung der KI wird den Einsatz erheblicher Ressourcen erfordern, um solche Systeme zu entwerfen, zu entwickeln, zu testen und zu warten und so sicherzustellen, dass KI im Einklang mit geltendem Recht und sozial verantwortlich eingesetzt wird und reale oder wahrgenommene unbeabsichtigte Schäden minimiert werden.
„Our commercial product, Papzimeos (zopapogene imadenovec-drba, PRGN-2012), is the first and only US Food and Drug Administration ("FDA") approved therapy for the treatment of adults with recurrent respiratory papillomatosis ("RRP")."
Unser kommerzielles Produkt Papzimeos (zopapogene imadenovec-drba, PRGN-2012) ist die erste und einzige von der US-Arzneimittelbehörde FDA zugelassene Therapie zur Behandlung erwachsener Patienten mit rezidivierender respiratorischer Papillomatose (RRP).
Filings Reviewed: 10-K 2026-03-25 · 10-K 2025-03-19 · 10-Q 2026-05-13 · 10-Q 2025-11-13 · 10-Q 2025-08-12 · 10-Q 2025-05-14
Rated on July 10, 2026 · How the Rating Is Built
Growth Score
2 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -28.9% failed
- More than 10% revenue growth is expected for the coming year 84.1% passed
- Share count grows by less than 3% a year 15.0% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -780.9% failed
- Gross margin at 40% or higher and without meaningful erosion 37.1% failed
- Goodwill from acquisitions does not grow faster than revenue 9.7% failed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 250 m failed
- Return on capital at 15% or higher, or up versus two years ago -89.3% failed
- Insiders hold at least 10% or are net buyers 13.7% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 98.4% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 4
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.03 | -0.06 – 0.02 | 124 | – | 3 |
| 12/31/2027 | 0.20 | 0.09 – 0.34 | 229 | – | 3 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.01 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.07 | – | 1 | -3.10 | -1,657.70 | -8 | -9 |
| 2025: Q1 | -0.18 | – | 1 | 25.90 | -4,038.30 | -16 | -17 |
| 2025: Q2 | -0.09 | – | 1 | 19.40 | -3,112.40 | -19 | -20 |
| 2025: Q3 | -0.49 | – | 3 | 206.60 | -5,008.40 | -29 | -30 |
| 2025: Q4 | -0.08 | – | 5 | 283.60 | -514.90 | -24 | -24 |
| 2026: Q1 | -0.03 | – | 23 | 1,633.90 | -34.10 | -44 | -44 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 191 | -125 | -187 | -1.58 | -56 | 560 | 949 |
| 2017 | 231 | -138 | -117 | -0.98 | -104 | 534 | 847 |
| 2018 | 161 | -506 | -509 | -3.93 | -124 | 363 | 716 |
| 2019 | 32 | -86 | -171 | -1.11 | -77 | 72 | 456 |
| 2020 | 32 | -86 | -171 | -1.02 | -77 | 67 | 315 |
| 2021 | 14 | -92 | -92 | -0.47 | -56 | 107 | 360 |
| 2022 | 27 | -76 | 28 | 0.14 | -65 | 126 | 216 |
| 2023 | 6 | -100 | -96 | -0.39 | -67 | 119 | 151 |
| 2024 | 4 | -135 | -126 | -0.47 | -68 | 39 | 145 |
| 2025 | 10 | -107 | -251 | -0.82 | -88 | 21 | 157 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Precigen, Inc., ein biopharmazeutisches Unternehmen in der Entdeckungs- und klinischen Phase, entwickelt Gen- und Zelltherapien mit Präzisionstechnologie zur gezielten Behandlung von Krankheiten in den Bereichen Immunonkologie, Autoimmunerkrankungen und Infektionskrankheiten.
| Employees | 160 |
|---|---|
| Headquarters | Germantown, MD |
| Address | 20374 Seneca Meadows Parkway, 20876 Germantown, United States |
| Phone | 301 556 9900 |
| Website | precigen.com |
| IPO Date | 8. Aug 2013 |
| ISIN | US74017N1054 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Randal J. Kirk J.D. | Executive Chairman | 1953 |
| Helen Sabzevari MPH, Ph.D. | President, CEO & Director | 1962 |
| Harry Thomasian Jr. | Chief Financial Officer | 1962 |
| Rutul R. Shah | Chief Operating Officer | 1981 |
| Donald P. Lehr J.D., Ph.D. | Chief Legal Officer & Corporate Secretary | 1975 |
| Phil Tennant | Chief Commercial Officer | 1970 |
| Steven M. Harasym | VP & Head of Investor Relations | – |
| Douglas E. Brough Ph.D. | Senior VP & Head of Research | 1955 |
| Bryan T. Butman Ph.D. | Senior VP & Head of CMC | 1953 |
| Amy R. Lankford Ph.D. | Senior VP & Head of Clinical Operations and Regulatory Affairs | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 31. Jul 2026 | Thomasian Harry Jr. | Chief Financial Officer | Sell | 100,000 | 6.06 | 606,000 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.